enVVeno Medical (NVNO) Projected to Post Earnings on Thursday

enVVeno Medical (NASDAQ:NVNO) will likely be releasing its results before the market opens on Thursday, February 26th. Analysts expect enVVeno Medical to post earnings of ($9.80) per share for the quarter.

enVVeno Medical Stock Performance

enVVeno Medical stock traded up $1.71 during trading on Friday, reaching $11.70. 37,377 shares of the company’s stock were exchanged, compared to its average volume of 25,116. enVVeno Medical has a 52-week low of $8.67 and a 52-week high of $196.70. The firm has a market cap of $7.72 million, a price-to-earnings ratio of -0.31 and a beta of 1.07. The company’s 50-day moving average is $11.12 and its two-hundred day moving average is $31.66.

Institutional Investors Weigh In On enVVeno Medical

A number of hedge funds have recently bought and sold shares of NVNO. Geode Capital Management LLC raised its position in shares of enVVeno Medical by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 199,509 shares of the company’s stock valued at $796,000 after purchasing an additional 2,211 shares in the last quarter. Creative Planning bought a new stake in shares of enVVeno Medical in the second quarter worth $54,000. Jane Street Group LLC bought a new stake in shares of enVVeno Medical in the second quarter worth $51,000. Finally, Perceptive Advisors LLC acquired a new stake in enVVeno Medical in the second quarter valued at $5,127,000. Institutional investors and hedge funds own 34.71% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of enVVeno Medical in a research report on Monday, December 29th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce”.

About enVVeno Medical

enVVeno Medical, Inc is a clinical‐stage medical device company focused on the development and commercialization of subcutaneous vascular access systems for patients requiring repeated or long‐term intravenous therapy. Through its proprietary Freedom® platform, the company aims to offer an implantable alternative to traditional peripherally inserted central catheters (PICCs) and external tunneled catheters, addressing complications such as infection risk, dislodgement and patient discomfort.

The company’s lead product candidate, the Freedom PICC System, consists of a low‐profile, subcutaneous port connected to a flexible catheter designed for peripheral insertion.